Toronto Dominion Bank Decreases Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Toronto Dominion Bank lessened its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 43.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 3,706 shares of the medical research company's stock after selling 2,864 shares during the period. Toronto Dominion Bank's holdings in Bio-Rad Laboratories were worth $1,240,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Capital Advisors Ltd. LLC grew its holdings in shares of Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock valued at $26,000 after buying an additional 62 shares during the period. UMB Bank n.a. boosted its stake in shares of Bio-Rad Laboratories by 140.6% during the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock worth $26,000 after buying an additional 45 shares during the last quarter. Gladius Capital Management LP bought a new position in Bio-Rad Laboratories in the third quarter valued at approximately $32,000. Headlands Technologies LLC bought a new stake in shares of Bio-Rad Laboratories during the 2nd quarter worth approximately $51,000. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at approximately $55,000. Institutional investors own 65.24% of the company's stock.

Analysts Set New Price Targets

BIO has been the topic of several recent analyst reports. StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, November 1st. Citigroup upped their price objective on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 target price for the company. Finally, Royal Bank of Canada increased their price target on Bio-Rad Laboratories from $369.00 to $481.00 and gave the company an "outperform" rating in a research note on Monday, December 9th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, Bio-Rad Laboratories presently has an average rating of "Moderate Buy" and an average target price of $394.20.

Bio-Rad Laboratories Stock Down 1.7 %

NYSE BIO traded down $5.67 on Tuesday, hitting $337.28. 226,465 shares of the company were exchanged, compared to its average volume of 241,433. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The stock has a fifty day moving average of $341.35 and a 200-day moving average of $322.07. The company has a market cap of $9.44 billion, a PE ratio of -12.34 and a beta of 0.90. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping analysts' consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The company had revenue of $649.70 million for the quarter, compared to analyst estimates of $628.18 million. During the same period in the prior year, the firm earned $2.33 earnings per share. Bio-Rad Laboratories's revenue for the quarter was up 2.8% on a year-over-year basis. As a group, analysts forecast that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.